Schonfeld Strategic Advisors’s Structure Therapeutics GPCR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.97M	Buy	165,426 +156,699	+1,796%	+$10.7M	0.06%	353
2025 Q4	$607K	Buy	+8,727	New	+$356K	﹤0.01%	1318
2025 Q3	–	Sell	-321,591	Closed	-$6.67M	–	2340
2025 Q2	$6.67M	Buy	+321,591	New	+$7.07M	0.05%	467
2024 Q3	–	Sell	-216,413	Closed	-$8.5M	–	2179
2024 Q2	$8.5M	Buy	+216,413	New	+$8.89M	0.05%	398
2024 Q1	–	Sell	-9,200	Closed	-$375K	–	2189
2023 Q4	$375K	Sell	9,200 -15,400	-63%	-$883K	﹤0.01%	1368
2023 Q3	$1.24M	Buy	+24,600	New	+$793K	0.01%	953

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Schonfeld Strategic Advisors's GPCR Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Structure Therapeutics (GPCR) stake by 1,796% in Q1 2026, buying an estimated $10.7M and bringing the position to 165,426 shares worth $7.97M. The position accounts for 0.06% of the portfolio, ranked #353.

Schonfeld Strategic Advisors first reported a position in GPCR in Q3 2023 and has held it in 6 quarters since. The position peaked at $8.5M in Q2 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Schonfeld Strategic Advisors held 165,426 shares of Structure Therapeutics worth $7.97M as of Q1 2026.
Schonfeld Strategic Advisors bought 156,699 Structure Therapeutics shares in Q1 2026, an estimated $10.7M.
Structure Therapeutics made up 0.06% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #353 holding.
Schonfeld Strategic Advisors first reported a position in Structure Therapeutics in Q3 2023 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's Structure Therapeutics position peaked at $8.5M in Q2 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.